These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20361306)

  • 1. Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
    Wu CZ; Pei D; Hsieh AT; Wang K; Lin JD; Lee LH; Chu YM; Hsiao FC; Pei C; Hsia TL
    Arch Pharm Res; 2010 Mar; 33(3):411-6. PubMed ID: 20361306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
    Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
    Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.
    Li Y; Xu L; Shen J; Ran J; Zhang Y; Wang M; Yan L; Cheng H; Fu Z
    Diabetes Res Clin Pract; 2010 Apr; 88(1):42-7. PubMed ID: 20060192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
    Van Gaal LF; Van Acker KL; De Leeuw IH
    Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
    Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
    Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.
    Singhal P; Caumo A; Cobelli C; Taylor R
    Metabolism; 2005 Jan; 54(1):79-84. PubMed ID: 15562384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.
    Cesur M; Corapcioglu D; Gursoy A; Gonen S; Ozduman M; Emral R; Uysal AR; Tonyukuk V; Yilmaz AE; Bayram F; Kamel N
    Diabetes Res Clin Pract; 2007 Feb; 75(2):141-7. PubMed ID: 16815586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
    Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
    Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide as monotherapy in Type 2 diabetes.
    Gomis R
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S133-5. PubMed ID: 10522838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
    Wolffenbuttel BH; Nijst L; Sels JP; Menheere PP; Müller PG; Kruseman AC
    Eur J Clin Pharmacol; 1993; 45(2):113-6. PubMed ID: 8223830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
    Rizzo MR; Barbieri M; Grella R; Passariello N; Paolisso G
    Diabetes Metab; 2005 Jun; 31(3 Pt 1):255-60. PubMed ID: 16142016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM).
    Wajchenberg BL; Santomauro AT; Porrelli RN
    Diabetes Res Clin Pract; 1993 May; 20(2):147-54. PubMed ID: 8375268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
    Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
    Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
    Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
    Nattrass M; Lauritzen T
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Repaglinide (NN-623)].
    Kaku K
    Nihon Rinsho; 1997 Nov; 55 Suppl():180-5. PubMed ID: 9434464
    [No Abstract]   [Full Text] [Related]  

  • 20. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
    Culy CR; Jarvis B
    Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.